Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Mirror Image who wrote (1583)	12/15/2015 2:48:37 AM
From: Mirror Image	Read Replies (1) \| Respond to of 2026

And just to make myself clear on this subject. The Seeking Alpha Author took that entry on the 10Q as Open Vitaros purchases / as a future receivables. I believe his notion of this entry to be incorrect ( he didn't do a good job in that respect ). In my opinion, these are expenses that Apricus will incur in the future and have nothing to do with the level of interest in Vitaros from our partners. I think it has to do with expenses that are forecasted and have to do with "moving the ball forward" on all of Apricus' pipeline. As you can see, this situation also plays to my theory on Management "expecting" positive news during the 1Q 2016. If I am correct, they have $8.3 M in purchase orders that they have committed to. They haven't secured financing as of yet. Why would they be sitting on their hands?